Shanghai Fosun Pharma (Group) Co., Ltd. (referred to as "Fosun Pharma" for short, stock code 600 196) was established on 1994 and listed on the Shanghai Stock Exchange in August, 1998. It is a leading listed company in China pharmaceutical industry.
2014 February 18, Fosun Pharma joined hands with TPG to acquire the parent company of United Family, a domestic high-end medical service provider in China, for US-China mutual benefit.
Fosun Pharma takes the modern biomedical health industry as the core, seizes the rapid growth of China's pharmaceutical market and the great opportunity for China enterprises to enter the global mainstream pharmaceutical market, strategically covers many important links in the pharmaceutical health industry chain such as R&D, manufacturing, distribution and terminal, and forms a large-scale specialized pharmaceutical health industry group with drug R&D and manufacturing as the core, leading the market position in medical services, medical diagnosis and medical devices in pharmaceutical circulation and other fields, and in R&D and innovation, marketing, mergers and acquisitions and talent building.
Fosun Pharma pays attention to innovative research and development, has a national enterprise technology center, and has established efficient international research and development teams in Shanghai, Chongqing and the United States. The company's research and development focuses on the fields of metabolism and digestive tract, cardiovascular, anti-tumor and immunomodulation, nervous system and anti-infection, and its main products occupy a leading position in their respective market segments. In China, Fosun Pharma has gained competitive advantages in the market segments such as liver disease, diabetes, tuberculosis and clinical diagnosis products. In the global market, Fosun Pharma has also become the leader of antimalarial drugs.
While focusing on the development of core pharmaceutical business, Fosun Pharma actively expands the field of medical services and further consolidates its competitive advantages in the fields of medical diagnosis and medical devices. At present, Fosun Pharma has established a solid foundation in the domestic high-end and specialized medical services. Fosun Pharma is also the second largest shareholder of Sinopharm Holdings, the largest pharmaceutical circulation enterprise in China, and owns leading retail chain brands such as Fu Mei Pharmacy and Golden Elephant Pharmacy, forming a pharmaceutical retail pattern centered on Shanghai and Beijing and facing the national development.
Fosun Pharma adheres to the principle of sustainable development and incorporates social responsibility into the long-term strategy of enterprise development. In the process of business development, Fosun Pharma has always been grateful and strives to become a company that satisfies society, government, employees and shareholders.
Keep innovating and enjoy health. Facing the future, Fosun Pharma will continue to take the promotion of human health as its mission, adopt the strategic development means of "endogenous growth, external expansion and integrated development", continuously improve its innovation ability, service ability, integration ability and internationalization ability, efficiently operate, manage and invest in outstanding enterprises in the industry, and become a leading enterprise providing healthy products and services.